Why the study?
The effectiveness of SARS-CoV-2 therapeutic antibodies has been compromised by mutations in variants of concern that escape neutralizing antibodies.
Population
SARS-CoV-2 variants of concern and infected hamsters
Comparison
Human neutralizing antibody targeting the spike receptor-binding domain
Design
Preclinical in vitro and in vivo neutralization and structural study
Authors
Loading...
Should not yet alter clinical nAb or vaccine strategies; leaves open the therapeutic potential of this unconventional conserved RBD epitope.
A newly identified human monoclonal antibody broadly neutralizes SARS-CoV-2 Omicron variants and prevents severe lung pathology in a hamster model, highlighting a conserved therapeutic target.
Stein et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: